A5003775887- Alzheimer's disease research and treatments
- Dementia and Cognitive Impairment Research
- Genetic Associations and Epidemiology
- Amyotrophic Lateral Sclerosis Research
- Bioinformatics and Genomic Networks
- Cerebrospinal fluid and hydrocephalus
- Pregnancy and preeclampsia studies
- Intracerebral and Subarachnoid Hemorrhage Research
- Cholinesterase and Neurodegenerative Diseases
- Neuroinflammation and Neurodegeneration Mechanisms
- Neurological Disease Mechanisms and Treatments
- Parkinson's Disease Mechanisms and Treatments
- Blood Coagulation and Thrombosis Mechanisms
- Nuclear Receptors and Signaling
- Mitochondrial Function and Pathology
- Drug Transport and Resistance Mechanisms
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Genetic Neurodegenerative Diseases
- Computational Drug Discovery Methods
- Birth, Development, and Health
- Neurological Disorders and Treatments
- Diet and metabolism studies
- Prion Diseases and Protein Misfolding
- Folate and B Vitamins Research
- Reproductive System and Pregnancy
University of Eastern Finland
2014-2023
Genomics (United Kingdom)
2020
University of Pennsylvania
2020
Kuopio University Hospital
2010-2019
Finland University
2012-2018
Boston University
2018
Erasmus MC
2018
Framingham Heart Study
2018
Institute for Neurodegenerative Disorders
2018
The University of Texas Health Science Center at San Antonio
2018
Mild cognitive impairment (MCI) is considered as a transition phase between normal aging and Alzheimer's disease (AD). MCI confers an increased risk of developing AD, although the state heterogeneous with several possible outcomes, including even improvement back to cognition. We sought determine serum metabolomic profiles associated progression diagnosis AD in prospective study. At baseline assessment, subjects enrolled study were classified into three diagnostic groups: healthy controls...
To assess the relationship between Alzheimer disease (AD)-related pathologic changes in frontal cortical brain biopsy and AD biomarkers ventricular vs lumbar CSF, to evaluate relationships of CSF with final clinical diagnosis AD.In 182 patients presumed normal pressure hydrocephalus (152 known APOE carrier status), Aβ plaques tau biopsies were correlated Aβ42, total tau, p-tau levels measured by ELISA. In a median follow-up 2.0 years, 51 developed dementia.The had lower (p = 0.009) Aβ42 than...
Nutrition is an important modifiable risk factor in Alzheimer's disease. Previous trials of the multinutrient Fortasyn Connect showed benefits mild disease dementia. LipiDiDiet investigated effects on cognition and related measures prodromal Here, we report 24-month results trial.LipiDiDiet was a randomised, controlled, double-blind, parallel-group, multicentre trial (11 sites Finland, Germany, Netherlands, Sweden), with optional 12-month double-blind extensions. The enrolled individuals...
The role of the apolipoprotein E (APOE) ε4 allele as an effect modifier in lifestyle interventions to prevent cognitive impairment is still unclear.To examine whether APOE modifies previously reported significant benefits a multidomain intervention (prespecified subgroup analysis).The Finnish Geriatric Intervention Study Prevent Cognitive Impairment and Disability (FINGER) was randomized clinical trial 6 centers across Finland (screening randomization performed from September 7, 2009,...
Abstract Due to the significant clinical overlap between frontotemporal lobar degeneration (FTLD) spectrum disorders and late-onset primary psychiatric (PPD), diagnostic biomarkers reflecting different underlying pathophysiologies are urgently needed. Thus far, elevated cerebrospinal fluid (CSF) levels of neurofilament light chain (NfL) have been reported in various neurological conditions. Furthermore, recent advancements ultrasensitive analytical methods (e.g., single molecule array,...
Alzheimer9s disease (AD) is a heterogeneous entity presenting as sporadic and familial disease.In AD, there evidence for genetic linkage to yet undefined gene on chromosome 14 in early-onset pedigrees 19 late-onset pedigrees. In few kindreds, were mutations the amyloid precursor 21. There an increased frequency of apolipoprotein E (ApoE) epsilon 4 allele patients with AD. We studied clinical presentation profile cognitive deficits 58 AD at early stage disease. divided into subgroups (SLO)...
WE measured tau concentrations in cerebrospinal fluid (CSF) samples taken during the lifetime of 43 patients with Alzheimer's disease (AD) and correlated these values neurofibrillary tangle (NFT) scores as well glial fibrillary acidic protein (GFAP) expression a marker astrocytosis brain post-mortem. The CSF showed positive correlation neocortical NFT (r = 0.44, p < 0.005), while GFAP immmunoreactivity did not correlate tau. This study reveals high variation neuropathologically confirmed AD...
<h3>OBJECTIVE</h3> Recent evidence indicates that the apolipoprotein E (ApoE) ε4 allele is a risk factor for developing Alzheimer's disease. It has also been proposed it associated with increased counts of amyloid plaques and neurofibrillary tangles in turn are neuropathological hallmarks initially appearing medial temporal lobe structures In this study, effect ApoE on volume entorhinal cortex was evaluated vivo. <h3>METHODS</h3> The measured MR images using recently designed histology based...
OBJECTIVES--The epsilon 4 allele of apolipoprotein E (ApoE) is a risk factor for late onset Alzheimer9s disease. ApoE present in senile plaques, neurofibrillary tangles, and cerebrovascular amyloid, it implicated synaptogenesis. The effect polymorphism on the volumes hippocampus, amygdala, frontal lobe was studied. hypothesis that patients with disease carrying have more pronounced atrophy. relation cerebral blood flow cortical areas also assessed. METHODS--Fifty eight at early stage 34...
A causative association between diabetes mellitus (DM) and Alzheimer's disease (AD) has been suggested based on clinical epidemiological studies. One hypothesis is that the link DM AD related to function of insulin-degrading enzyme (IDE), an degrades not only insulin pancreatic amylin but also beta-amyloid (Abeta). Thus, in diabetics, Abeta might compete for IDE this lead increase Abeta. The objective study was test hyperinsulinaemia can elevate levels thus contribute pathology...
Longitudinal changes of cerebrospinal fluid (CSF) biomarkers in Alzheimer's disease (AD) have been studied, but there are few consistent conclusions and even less is known about their variation during the different stages disease. We hypothesized that CSF biomarker values would correlate with progression cognitive decline AD. One hundred thirty-one memory clinic patients [56 AD, 57 mild impairment (MCI), 10 other neurological disorders, eight unimpaired subjects] underwent a clinical...
Background Frontotemporal lobar degeneration (FTLD) and primary psychiatric disorders (PPD) are characterised by overlapping clinical features but different aetiologies. Here, we assessed for the first time potential of blood glial fibrillar acidic protein (GFAP), marker astrogliosis, as a discriminative prognostic tool in FTLD PPD. Methods The levels GFAP serum (sGFAP) patients with (N=107) PPD (N=44) whole samples (bGFAP) from (N=10), (N=10) healthy controls (N=18) were measured. We...
The APOE ε4 variant and hippocampal atrophy in Alzheimer's disease Lewy body dementia: a systematic review of magnetic resonance imaging studies therapeutic relevance ,
To understand the relation between risk genes for Alzheimer's disease (AD) and their influence on biomarkers AD, we examined association of AD in Finnish cohort with single nucleotide polymorphisms (SNPs) from top AlzGene loci, genome-wide studies (GWAS), candidate gene studies; tested correlation these SNPs markers Aβ(1-42), total tau (t-tau), phosphorylated (p-tau) cerebrospinal fluid (CSF).We 25 genetic clinical our comprised 890 patients 701-age matched healthy controls using logistic...
3% of the population develops saccular intracranial aneurysms (sIAs), a complex trait, with sporadic and familial form. Subarachnoid hemorrhage from sIA (sIA-SAH) is devastating form stroke. Certain rare genetic variants are enriched in Finns, isolate small founder bottleneck events. As sIA-SAH incidence Finland >2× increased, such may associate Finnish population. We tested 9.4 million for association 760 patients (enriched sIA), 2,513 matched controls case-control status number sIAs. The...
CAIDE Dementia Risk Score is the first validated tool for estimating dementia risk based on a midlife profile.This observational study investigated longitudinal associations of with brain MRI, amyloid burden evaluated PIB-PET, and detailed cognition measures.FINGER participants were at-risk elderly without dementia. was calculated using data from previous national surveys (mean age 52.4 years). In connection to baseline FINGER visit (on average 17.6 years later, mean 70.1 years), 132...